Adult Vaccines Market, by Vaccine (Influenza, Tetanus/Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, and Others), by Vaccine Type (Monovalent and Multivalent), by Technology (Live Attenuated

Adult Vaccines Market, by Vaccine (Influenza, Tetanus/Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, and Others), by Vaccine Type (Monovalent and Multivalent), by Technology (Live Attenuated Vaccines, Inactivated Viral or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Conjugate Vaccines), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Vaccines refer to the biological preparation that improves immunity to fight against a particular disease. Vaccines comprise suspensions formulated from weakened, killed or fragmented microorganisms, toxins or antibodies that are administered to a patient, with a primary intention to prevent a disease. Vaccines offer active immunity against specific harmful and disease causing agents by stimulating the immune system to attack the agent. Vaccines helps to protect individuals against serious and fatal diseases such as influenza and measles among others. Adult immunization that includes administration of licensed vaccine provided to patients aged 18 years and older, for medical indications. Vaccines are routinely administered to eliminate the infectious diseases among infants and children, however the Centers of Disease Control & Prevention (CDC), 2017, also recommends adults to periodically take up vaccination, referred to as adult vaccines. According to the CDC 2015, 30% of the patients from mission Healthy People program in the U.S. 2020 opted for shingles vaccine and were reported to be safe from preventable illness. Adult vaccines are given to age group to 18 year old and above.

Market Dynamics

Market players are increasingly focusing on creating vaccinations for illnesses having the highest risk of spreading like an epidemic. For instance, in February 2017, an India-based drug firm, Cipla, in collaboration with Serum Institute of India, introduced Hepatitis B vaccine for adults in the country. The disease affects chronically over 40 million people in 2018 in the country, as per India’s Universal Immunization Program. Moreover, Dynavax Technologies Corporation, Biopharmaceutical Company received the United States Food and Drug Administration (U.S.FDA) approval in 2018, for its two-dosed Hepatitis-B vaccine indicated for adults aged 18 years and older.

Key features of the study:

• This report provides an in-depth analysis of the global adult vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global adult vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer, Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global adult vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global adult vaccines market

Detailed Segmentation:

• Global Adult Vaccines Market, By Vaccines:
• Influenza
• Tetanus, Diphtheria, Pertussis (Td/Tdap)
• Varicella
• Human Papillomavirus
• Zoster
• Measles, Mumps, Rubella (MMR)
• Pneumococcal
• Hepatitis
• Others
• Global Adult Vaccines Market, By Vaccine Type:
• Monovalent
• Multivalent
• Global Adult Vaccines Market, By Technology:
• Live Attenuated Vaccines
• Inactivated Viral/Bacterial Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Conjugate Vaccines
• Global Adult Vaccines Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• GlaxoSmithKline Plc *
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Merck & Co., Inc.
• Sanofi Pasteur
• Pfizer, Inc.
• CSL Limited
• Johnson & Johnson
• Serum Institute of India
• Medimmune
• AstraZeneca Plc.

“*” marked represents similar segmentation in other categories in the respective section.